Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.905 +0.055 (+2.97%)

Delayed Quote Updated: 2:47 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 06, 2023

Via Benzinga

Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday ↗

January 06, 2023

Via Benzinga

Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket ↗

January 06, 2023

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 06, 2023

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

Via InvestorPlace

What 6 Analyst Ratings Have To Say About Fate Therapeutics ↗

January 05, 2023

Via Benzinga

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

January 05, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

Cathie Wood Can't Keep Hands Off Tesla As Holiday Season Binge Grows To Nearly Half A Million Shares ↗

January 04, 2023

Cathie Wood-led ARK Investment Management bought 21,050 shares of Tesla Inc (NASDAQ: TSLA) on Wednesday at an estimated valuation of over $2.39 million.

Via Benzinga

Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday ↗

January 04, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Cathie Wood Loads Up Another $2M In Tesla While Elon Musk Urges Employees To Look Beyond Stock Plunge ↗

December 28, 2022

As Tesla Inc (NASDAQ: TSLA) shares witnessed a surprise rebound on Wednesday, Cathie Wood-led ARK Investment Management

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗

December 22, 2022

Via Benzinga

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

December 13, 2022

Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models

From Fate Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗

December 15, 2022

Via Benzinga

Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

December 12, 2022

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.

Via Benzinga

RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗

December 12, 2022

U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

December 12, 2022

From GT Biopharma, Inc.

Via GlobeNewswire

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

December 10, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

December 10, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via TheNewswire.com

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors

November 07, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

November 04, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

November 03, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

November 03, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Preview: Fate Therapeutics's Earnings ↗

November 02, 2022

Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Fate...

Via Benzinga

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers ↗

October 25, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via Benzinga

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

October 24, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

October 05, 2022

From Fate Therapeutics, Inc.

Via GlobeNewswire

Tesla, Meta, NVIDIA And Other Big Losers From Tuesday ↗

September 14, 2022

U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Apple, Amazon, HP And Other Big Losers From Friday ↗

August 29, 2022

U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.